Skip to main content

Prokidney Corp.

PROK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001850270

In the last 90 days, Prokidney Corp. insiders filed 0 open-market purchases and 1 sale; 71 institutions reported holding it in 13F filings for Q2 2026, worth $99.5M in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding Prokidney Corp. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of PROK: Q1 2022 compared with Q2 2022
MeasureQ1 2022Q2 2022Change
Holders8067−13
Shares23.4M19.2M−4.24M (−18.1%)
Value$232.0M$191.2M−$40.8M (−17.6%)

New holders (10)

Institutions that held Prokidney Corp. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to PROK in Q2 2022
InstitutionSharesValue% of portfolio
UBS Oconnor LLC362,372$3.61M0.04%
Qube Research & Technologies Ltd306,764$3.05M0.02%
K2 Principal Fund, L.P.136,937$1.37M0.23%
Ergoteles LLC62,981$627.0K0.02%
Goldman Sachs Group Inc43,400$432.0K0.00%
Exos Asset Management LLC42,201$422.0K0.22%
Meteora Capital, LLC42,299$421.0K0.08%
Clear Street LLC20,000$199.0K0.02%
UBS Group AG1,506$15.0K0.00%
Tower Research Capital LLC (TRC)653$6.00K0.00%

Sold out (23)

Institutions that held Prokidney Corp. at the end of Q1 2022 and filed for Q2 2022 without it.